Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer

Journal of the Egyptian National Cancer Institute

Table 3 The safety profile of patients suffering from recurrent or metastatic head and neck cancer

Sr. no.	Adverse drug reaction	Grade of ADR as per CTCAE system	Cohort 1 Incidence proportion (%)	Cohort 2 Incidence proportion (%)
1	Neutropenia	Grade II	12	11
2	Oral mucositis	Grade I	6	4
3	Peripheral neuropathy	Grade II	4	2
4	Fatigue	Grade II	9	7
5	Nausea	Grade I	8	6
6	Vomiting	Grade II	4	3
7	Weight loss	Grade I	3	2
8	Anemia	Grade II	7	4
9	Skin rash	Grade I	4	4

ADR adverse drug reaction, CTCAE version 5 common terminology criteria for adverse events. Data presented as percentage. Data analyzed by Fisher’s exact test followed by Tukey’s multiple comparison test (CI = 95%, P < 0.05)